Item 8.01 Other Events.
On December 10, 2021, Bellicum Pharmaceuticals, Inc. (the "Company") received a
letter from the Listing Qualifications Hearings Department of The Nasdaq Stock
Market LLC notifying the Company that it has regained compliance with Listing
Rule 5550(b)(1), which requires stockholders' equity of at least $2.5 million
for continued listing of the company's common stock. Accordingly, the Company
has regained compliance with the continued listing requirements of The Nasdaq
Capital Market. The notification follows the company's recent completion of its
private placement of equity securities for gross proceeds of approximately $35.0
million, before deducting placement agent commissions and offering expenses
payable by the Company.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses